CCR6 is required for IL-23-induced psoriasis-like inflammation in mice

Journal of Clinical Investigation

Volumn 119, Issue 8, 2009, Pages 2317-2329

  Hedrick, Michael N ^a   Lonsdorf, Anke S ^b,c   Shirakawa, Aiko Konno ^a,f   Lee, Chyi Chia Richard ^b   Liao, Fang ^a,g   Singh, Satya P ^a   Zhang, Hongwei H ^a   Grinberg, Alexander ^d   Love, Paul E ^d   Hwang, Sam T ^b,e   Farber, Joshua M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR6; COMPLEMENTARY DNA; GENOMIC DNA; INTERLEUKIN 22; INTERLEUKIN 23; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; DERMIS; DRUG TARGETING; EPIDERMIS; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE SYSTEM; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY DISEASE; LYMPH NODE; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSORIASIS; SKIN DISEASE; SOUTHERN BLOTTING; SPLEEN CELL; TH17 CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HOMEODOMAIN PROTEINS; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKINS; MICE; MICE, INBRED C57BL; PSORIASIS; RECEPTORS, CCR6;

EID: 68849104003     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37378     Document Type: Article

References (86)

1. Schon, M.P., and Boehncke, W.H. 2005. Psoriasis. N. Engl. J. Med. 352:1899-1912.
2. Lowes, M.A., Bowcock, A.M., and Krueger, J.G. 2007. Pathogenesis and therapy of psoriasis. Nature. 445:866-873.
3. Bowcock, A.M., and Krueger, J.G. 2005. Getting under the skin: the immunogenetics of psoriasis. Nat. Rev. Immunol. 5:699-711.
4. Nickoloff, B.J., and Nestle, F.O. 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113:1664-1675.
5. Gottlieb, A.B., et al. 2003. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139:1627-1632.
6. Papp, K.A., et al. 2005. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152:1304-1312.
7. Chaudhari, U., et al. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 357:1842-1847.
8. Reich, K., et al. 2005. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 366:1367-1374.
9. Cua, D.J., et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inf lammation of the brain. Nature. 421:744-748.
10. Murphy, C.A., et al. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198:1951-1957.
11. Langrish, C.L., et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201:233-240.
12. Blauvelt, A. 2008. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J. Invest. Dermatol. 128:1064-1067.
13. Pene, J., et al. 2008. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J. Immunol. 180:7423-7430.
14. Bettelli, E., Korn, T., and Kuchroo, V.K. 2007. Th17: the third member of the effector T cell trilogy. Curr. Opin. Immunol. 19:652-657.
15. Ouyang, W., Kolls, J.K., and Zheng, Y. 2008. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 28:454-467.
16. Lowes, M.A., et al. 2008. Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells. J. Invest. Dermatol. 128:1207-1211.
17. Guttman-Yassky, E., et al. 2008. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J. Invest. Dermatol. 128:1182-1191.
18. van Beelen, A.J., Teunissen, M.B., Kapsenberg, M.L., and de Jong, E.C. 2007. Interleukin-17 in inflammatory skin disorders. Curr. Opin. Allergy Clin. Immunol. 7:374-381.
19. Fitch, E., Harper, E., Skorcheva, I., Kurtz, S.E., and Blauvelt, A. 2007. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr. Rheumatol. Rep. 9:461-467.
20. Lee, E., et al. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199:125-130.
21. Zaba, L.C., et al. 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204:3183-3194.
22. Piskin, G., Sylva-Steenland, R.M., Bos, J.D., and Teunissen, M.B. 2006. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176:1908-1915.
23. Wilson, N.J., et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8:950-957.
24. Oppmann, B., et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 13:715-725.
25. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., and Gurney, A.L. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910-1914.
26. Manel, N., Unutmaz, D., and Littman, D.R. 2008. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 9:641-649.
27. Volpe, E., et al. 2008. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9:650-657.
28. McGeachy, M.J., et al. 2009. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 10:314-324.
29. Capon, F., et al. 2007. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122:201-206.
30. Cargill, M., et al. 2007. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80:273-290.
31. Nair, R.P., et al. 2008. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J. Invest. Dermatol. 128:1653-1661.
32. Nair, R.P., et al. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41:199-204.
33. Krueger, G.G., et al. 2007. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356:580-592.
34. Leonardi, C.L., et al. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 371:1665-1674.
35. Papp, K.A., et al. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 371:1675-1684.
36. Kopp, T., et al. 2003. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J. Immunol. 170:5438-5444.
37. Chan, J.R., et al. 2006. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203:2577-2587.
38. Zheng, Y., et al. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 445:648-651.
39. Ma, H.L., et al. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasislike skin inflammation. J. Clin. Invest. 118:597-607.
40. Sa, S.M., et al. 2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178:2229-2240.
41. Wolk, K., et al. 2004. IL-22 increases the innate immunity of tissues. Immunity. 21:241-254.
42. Wolk, K., et al. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 36:1309-1323.
43. Boniface, K., et al. 2007. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin. Exp. Immunol. 150:407-415.
44. Murphy, P.M., et al. 2000. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:145-176.
45. Gerard, C., and Rollins, B.J. 2001. Chemokines and disease. Nat. Immunol. 2:108-115.
46. Schon, M.P., and Ludwig, R.J. 2005. Lymphocyte trafficking to inflamed skin - molecular mechanisms and implications for therapeutic target molecules. Expert Opin. Ther. Targets. 9:225-243.
47. Sallusto, F., Mackay, C.R., and Lanzavecchia, A. 2000. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18:593-620.
48. Sallusto, F., Geginat, J., and Lanzavecchia, A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745-763.
49. Annunziato, F., et al. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204:1849-1861.
50. Acosta-Rodriguez, E.V., et al. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639-646.
51. Singh, S.P., Zhang, H.H., Foley, J.F., Hedrick, M.N., and Farber, J.M. 2008. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J. Immunol. 180:214-221.
52. Hirota, K., et al. 2007. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204:2803-2812.
53. Homey, B., et al. 2000. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164:6621-6632.
54. Liao, F., et al. 1999. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J. Immunol. 162:186-194.
55. Clark, R.A., et al. 2006. The vast majority of CLA+ T cells are resident in normal skin. J. Immunol. 176:4431-4439.
56. Teraki, Y., Miyake, A., Takebayashi, R., and Shiohara, T. 2004. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin. Exp. Dermatol. 29:658-663.
57. Farber, J.M. 2000. CCR6. In Cytokine reference. J.J. Oppenheim and M. Feldman, editors. Academic Press. London, United Kingdom/San Diego, California, USA. 2081-2086.
58. Varona, R., et al. 2001. CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. J. Clin. Invest. 107:R37-R45.
59. McDonald, K.G., et al. 2007. CC chemokine receptor 6 expression by B lymphocytes is essential for the development of isolated lymphoid follicles. Am. J. Pathol. 170:1229-1240.
60. Varona, R., Cadenas, V., Flores, J., Martinez, A.C., and Marquez, G. 2003. CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur. J. Immunol. 33:2937-2946.
61. Cook, D.N., et al. 2000. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity. 12:495-503.
62. Salazar-Gonzalez, R.M., et al. 2006. CCR6-mediated dendritic cell activation of pathogen-specific T cells in Peyer's patches. Immunity. 24:623-632.
63. Paradis, T.J., Cole, S.H., Nelson, R.T., and Gladue, R.P. 2008. Essential role of CCR6 in directing activated T cells to the skin during contact hypersensitivity. J. Invest. Dermatol. 128:628-633.
64. Varona, R., Cadenas, V., Gomez, L., Martinez, A.C., and Marquez, G. 2005. CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood. 106:18-26.
65. Lochner, M., et al. 2008. In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J. Exp. Med. 205:1381-1393.
66. Duerr, R.H., et al. 2006. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 314:1461-1463.
67. Liang, S.C., et al. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203:2271-2279.
68. Schulz, S.M., et al. 2008. Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J. Immunol. 181:7891-7901.
69. Zheng, Y., et al. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14:282-289.
70. Kopp, T., et al. 2001. Inflammatory skin disease in K14/p40 transgenic mice: evidence for interleukin-12-like activities of p40. J. Invest. Dermatol. 117:618-626.
71. Schmuth, M., et al. 2002. Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp. Dermatol. 11:135-142.
72. Ivanov, I.I., Zhou, L., and Littman, D.R. 2007. Transcriptional regulation of Th17 cell differentiation. Semin. Immunol. 19:409-417.
73. Gaffen, S.L. 2008. An overview of IL-17 function and signaling. Cytokine. 43:402-407.
74. Nograles, K.E., et al. 2008. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159:1092-1102.
75. Kleinewietfeld, M., et al. 2005. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood. 105:2877-2886.
76. Lowes, M.A., et al. 2005. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. U. S. A. 102:19057-19062.
77. Merad, M., et al. 2004. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat. Med. 10:510-517.
78. Le Borgne, M., et al. 2006. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity. 24:191-201.
79. Cella, M., et al. 2009. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 457:722-725.
80. Luci, C., et al. 2009. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat. Immunol. 10:75-82.
81. Sanos, S.L., et al. 2009. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat. Immunol. 10:83-91.
82. Satoh-Takayama, N., et al. 2008. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity. 29:958-970.
83. MacArthur, R.D., and Novak, R.M. 2008. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 47:236-241.
84. Tybulewicz, V.L., Crawford, C.E., Jackson, P.K., Bronson, R.T., and Mulligan, R.C. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 65:1153-1163.
85. Lee, S.J., and Nathans, D. 1988. Proliferin secreted by cultured cells binds to mannose 6-phosphate receptors. J. Biol. Chem. 263:3521-3527.
86. Belkaid, Y., et al. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194:1497-1506.